Merck & Co returns rights to Endocyte's vintafolide

18 June 2014

Shares of USA-based Endocyte (Nasdaq: ECYT) fell 19.7% to $6.20 in after-hours trading yesterday, after the company announced that it has regained the worldwide rights to vintafolide in all indications from US pharma giant Merck & Co (NYSE: MRK).

Following a comprehensive portfolio assessment, Merck, through a subsidiary, has decided that it will no longer pursue development of vintafolide. Just last month, Merck and Endocyte withdrew their European marketing approval application for the drug, after an independent monitoring board said that the PROCEED trial with vintafolide in combination with pegylated liposomal doxorubicin (PLD) versus PLD alone did not meet the pre-specified criteria for progression-free survival in patients with platinum-resistant ovarian cancer to allow continuation of the study.

Awaiting evaluation of NSCLC trial

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK